8 completed, 1 withdrawn. 4 Phase 4, 3 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 4 | Completed 4 |
| Phase 3 | 3 | Completed 3 |
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
Follow Osteoporosis, Post-menopausal: new trials by email Literature Review of Osteoporosis, Post-menopausal trials Research Report on Osteoporosis, Post-menopausal
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomes Romosozumab, Alendronate (Fosamax), Placebo Romosozumab - Osteoporosis, Post-menopausal | Phase 2 | Withdrawn | University of Pittsburgh | 2026-06-20 | 2026-06-04 | |
| Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women Teriparatide, Zoledronic Acid - Osteoporosis, Post-menopausal | Phase 4 | Completed | Eli Lilly and Company | 69 | 2009-07-01 | 2013-04-04 |
| Study of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis teriparatide - Osteoporosis, Post-Menopausal | Phase 3 | Completed | Eli Lilly and Company | 50 | 2003-11-01 | 2007-09-20 |
| A Study of the Treatment of Postmenopausal Women With Osteoporosis teriparatide 20 micrograms/day subcutaneous, salmon calcitonin 100 IU/day subcutaneous - Osteoporosis, Post-Menopausal | Phase 3 | Completed | Eli Lilly and Company | 104 | 2003-06-01 | 2007-10-12 |
| Bone Marker Changes With Teriparatide/Postmenopausal Osteoporosis Teriparatide - Osteoporosis, Post-Menopausal | Phase 4 | Completed | Eli Lilly and Company | 45 | 2003-04-01 | 2007-09-20 |
| Long Term Effects of Raloxifene Treatment on Bone Quality Raloxifene, Placebo - Osteoporosis, Post-Menopausal | Phase 4 | Completed | Eli Lilly and Company | 31 | 2003-04-01 | 2007-09-20 |
| Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene or Placebo raloxifene, Placebo - Osteoporosis, Post-Menopausal | Phase 4 | Completed | Eli Lilly and Company | 147 | 2003-03-01 | 2007-09-20 |
| PTH Comparison in Post Menopausal Women teriparatide 20 micrograms/day subcutaneous, calcitonin 100 IU/day subcutaneous - Osteoporosis, Post-Menopausal | Phase 3 | Completed | Eli Lilly and Company | 63 | 2002-12-01 | 2007-10-12 |
| Combination Osteogenic Therapy in Established Osteoporosis PTH 1-34, MFPSR-fluoride - Osteoporosis, Post-Menopausal | Phase 2 | Completed | US Department of Veterans Affairs | 1998-11-01 | 2009-01-21 |
Osteoporosis, Postmenopausal (9) · Osteoporosis (2)
Bone Diseases (9) · Bone Diseases, Metabolic (9) · Metabolic Diseases (9) · Musculoskeletal Diseases (9) · Nutritional and Metabolic Diseases (9) · Osteoporosis (7)
Teriparatide (5) · Injections, Subcutaneous (2) · Raloxifene Hydrochloride (2) · Alendronate (1) · Calcitonin (1) · Parathyroid Hormone (1) · Zoledronic Acid (1) · romosozumab (1) · salmon calcitonin (1)
Eli Lilly and Company (7) · US Department of Veterans Affairs (1) · University of Pittsburgh (1)
United States (5) · Canada (1) · China (1) · Mexico (1) · Netherlands (1) · Puerto Rico (1) · Russia (1) · Spain (1) · Taiwan (1)